Edition:
United States

Chimerix Inc (CMRX.OQ)

CMRX.OQ on NASDAQ Stock Exchange Global Market

5.00USD
4:00pm EDT
Change (% chg)

$-0.02 (-0.40%)
Prev Close
$5.02
Open
$5.02
Day's High
$5.05
Day's Low
$4.98
Volume
29,113
Avg. Vol
62,508
52-wk High
$6.63
52-wk Low
$3.67

Latest Key Developments (Source: Significant Developments)

Chimerix reports Q2 loss per share $0.36
Monday, 7 Aug 2017 07:00am EDT 

Aug 7 (Reuters) - Chimerix Inc :Chimerix announces second quarter 2017 financial results.Q2 loss per share $0.36.Q2 revenue $700,000 versus $1.8 million.Q2 revenue view $1.2 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S.  Full Article

Chimerix Q1 loss per share $0.38
Tuesday, 9 May 2017 07:00am EDT 

May 9 (Reuters) - Chimerix Inc :Chimerix announces first quarter 2017 financial results.Q1 loss per share $0.38.Q1 revenue $1.1 million versus $1.2 million.Q1 revenue view $1.4 million -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S.  Full Article

Chimerix Q4 loss per share $0.32
Thursday, 2 Mar 2017 07:00am EST 

Chimerix Inc : Chimerix announces fourth quarter and full year 2016 financial results . Q4 loss per share $0.32 . Q4 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S . Q4 revenue $2.0 million versus $3.1 million .Q4 revenue view $1 million -- Thomson Reuters I/B/E/S.  Full Article

Chimerix Q2 loss per share $0.39
Monday, 8 Aug 2016 07:30am EDT 

Chimerix Inc : Chimerix announces second quarter 2016 financial results . Q2 earnings per share view $-0.51 -- Thomson Reuters I/B/E/S .Q2 revenue $1.8 million versus I/B/E/S view $2 million.  Full Article

Chimerix Q1 loss per share $0.57
Monday, 9 May 2016 07:30am EDT 

Chimerix Inc : Chimerix Announces Top-Line Interim AdVise Data and First Quarter 2016 Financial Results . Q1 loss per share $0.57 . Q1 revenue $1.2 million . Q1 revenue view $2.8 million -- Thomson Reuters I/B/E/S .Q1 earnings per share view $-0.66 -- Thomson Reuters I/B/E/S.  Full Article

Chimerix Inc presents positive results from brincidofovir pivotal study in animal model for smallpox
Monday, 8 Feb 2016 02:03pm EST 

Chimerix Inc:Presents positive results from brincidofovir pivotal study in animal model for smallpox.Study met its primary endpoint of clinically and statistically significant (p<0.05) reduction in mortality for brincidofovir-treated animals compared with animals that received placebo.Final data from the rabbitpox study together with efficacy data from a mouse model of smallpox will be submitted to the FDA for discussion of next steps.  Full Article

Chimerix Inc announces top-line results from Phase 3 SUPPRESS Trial of Brincidofovir
Monday, 28 Dec 2015 07:30am EST 

Chimerix Inc:Announces top-line results from phase 3 suppress trial of brincidofovir.Says primary endpoint failures in both the prevention of CMV infections and mortality in the brincidofovir arm.Says plans to continue the programs testing brincidofovir in serious adenovirus infections and in smallpox.Primary endpoint failures in prevention of cmv infections, mortality in brincidofovir ARM driven by confirmed cases of GVHD.Says non-statistically significant increase in mortality in the brincidofovir arm compared to the control arm.Chimerix has elected to pause further enrollment in the phase 3 sustain and surpass trials in kidney transplant recipients.Says SUPPRESS did not achieve primary endpoint for prevention of clinically significant CMV infection after HCT.  Full Article

Chimerix initiates Phase 3 SUSTAIN and SURPASS Trials of Brincidofovir for Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients
Thursday, 22 Oct 2015 04:02pm EDT 

Chimerix Inc:Initiates Phase 3 SUSTAIN and SURPASS Trials of Brincidofovir for Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients.Topline data from SUPPRESS are anticipated in early 2016.  Full Article

BRIEF-Chimerix Inc appoints Heather Knight-Trent vice president of regulatory affairs

* Chimerix appoints Heather Knight-Trent, PHARMD, as vice president of regulatory affairs Source text for Eikon: Further company coverage: